<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1803">
  <stage>Registered</stage>
  <submitdate>16/01/2008</submitdate>
  <approvaldate>16/01/2008</approvaldate>
  <nctid>NCT00604006</nctid>
  <trial_identification>
    <studytitle>SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)</studytitle>
    <scientifictitle>SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP-02/07</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Spironolactone
Treatment: drugs - Placebo

Experimental: Group A - 

Placebo Comparator: Group B - 


Treatment: drugs: Spironolactone
25 mg tablets (placed in capsules for blinding) once daily.

Treatment: drugs: Placebo
Placebo (lactose in capsules for blinding) once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effectiveness of Spironolactone in preventing heart failure</outcome>
      <timepoint>1 year and 3 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Cost effectiveness of Spironolactone prevention</outcome>
      <timepoint>3 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Development of evidence of LV dysfunction, either systolic or diastolic, on echocardiography and/or symptomatic heart failure</outcome>
      <timepoint>1 year and 3 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in 6 minute walk test between the two groups</outcome>
      <timepoint>1 year and 3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in quality of life between the two groups</outcome>
      <timepoint>1 year and 3 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in left ventricular remodelling parameters</outcome>
      <timepoint>1 year and 3 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Was recruited to SCREEN-HF

          2. Has provided informed consent</inclusivecriteria>
    <inclusiveminage>60</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>1. Uncorrected hyperkalaemia

          2. eGFR &lt; 30 ml/min</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Alfred Hospital - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Monash University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Heart Foundation, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP
      level are in the top quintile will be offered participation in this study. Participants will
      be randomised to receive either spironolactone or placebo for three years. Participants will
      then be monitored for indications of heart failure. It is anticipated that the medication
      will reduce the development of heart failure in this group.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00604006</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Henry Krum, MBBS FRACP PhD</name>
      <address>Monash University / Alfred Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>